CHI3L1 and IL33/ST2L inhibit immune cell activity in the tumor microenvironment, which in turn helps tumor growth. Our innovative CHI3L1 neutralizing antibody and ST2L/IL-33 blocking antibody inhibit tumor growth in animal models and increase anti-tumor immune cell infiltration. We developed neutralizing antibodies targeting CHI3L1 and ST2L/IL-33, which will become novel immunotherapies for lung cancer.

The small molecule G protein Rab37 was identified to positively regulate the release of immunosuppressive substances, CHI3L1, IL-33 and ST2L. The newly developed neutralizing antibodies can effectively increase CD8+ T cells infiltration into the tumor microenvironment, which further inhibits tumor growth. Neutralizing antibodies targeting CHI3L1 and ST2L/IL-33 will become novel lung cancer immunotherapy.

The neutralizing blocking antibodies produced by this technology can further humanized to protein drug for the treatment of lung cancer or other related diseases in the future; it may also be used to manufacture test reagents related to the process of detecting lung cancer patients, including ELISA reagents. rapid test strips, or the development of cancer test chips in combination with nanotechnology.